key: cord-0830382-pf7cr8ve
authors: Chehab, Omar; El Zein, Said; Kanj, Amjad; Moghrabi, Adel; Sebastian, Joseph; Halboni, Adnan; Alkassis, Samer; Hor, Nivine El-; Briasoulis, Alexandros; Lieberman, Randy; Afonso, Luis; Chandrasekar, Pranatharthi; Abidov, Aiden
title: SARS-CoV-2 Viral Load and Cardiac Injury are Independent and Incremental Predictors of Adverse Outcome
date: 2021-08-13
journal: Mayo Clin Proc Innov Qual Outcomes
DOI: 10.1016/j.mayocpiqo.2021.08.005
sha: 3b6f9fef42b7d0b67b6937f49b56aef7ba0494b8
doc_id: 830382
cord_uid: pf7cr8ve

Objective To evaluate the association of the SARS-CoV-2 initial viral load (iVL) and the incidence of myocardial injury (MCI) in hospitalized patients with SARS-CoV-2 infection. Patients and Methods This is a retrospective longitudinal study of hospitalized patients who had a nasopharyngeal swab sample on admission that returned positive for SARS-CoV-2 by polymerase chain reaction between April 4 and June 5, 2020. The cycle threshold (Ct) value was used as a surrogate for the iVL level, with a Ct level ≤36 for elevated iVL, and >36 for low iVL. MCI was defined as having an elevated high-sensitivity cardiac troponin I >99th percentile upper reference limit. Results A total of 270 patients were included. Of these, 171 (63.3%) had an elevated iVL and 88 (32.6%) had MCI. There was no significant difference in the incidence of MCI in patients with low iVL compared to those with elevated iVL (28.3% vs 35.1%, p=0.25). In a multivariable model, MCI (OR: 3.86; 95% CI 1.80-8.34, p<0.001) and elevated iVL (OR: 4.21; 95% CI 2.06-8.61, p<0.001) were independent and incremental predictors of in-hospital mortality. Conclusion SARS-CoV-2 iVL level is not associated with increased incidence of MCI, though both parameters are strong independent and incremental predictors of mortality. Understanding the MCI mechanisms MCI allows for early focused interventions to improve survival, especially in patients with SARS-CoV-2 infection and high iVL.

Myocardial injury (MCI) , defined by elevated cardiac troponins, is common in patients with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection and appears to be associated with worse outcomes and mortality (1) (2) (3) . Mechanisms of cardiac injury in these patients include acute hypoxic respiratory failure, sepsis, tachycardia, thrombotic coronary obstruction, heart failure exacerbation, pulmonary embolism and SARS-CoV-2 associated myocarditis, among others (4) . Similarly, recent evidence suggests that elevated SARS-CoV-2 viral load on admission is linked to higher mortality (5, 6) .

The relationship between the initial SARS-CoV-2 initial viral load (iVL) level and MCI has not yet been well-defined. We hypothesized that a higher nasopharyngeal SARS-COV-2 iVL on presentation would be linked to increased cardiac injury, and that both elevated SARS-CoV-2 iVL and cardiac injury would increase in-hospital mortality.

This is a retrospective study of adult patients (≥18 years) with symptomatic SARS-CoV-2 infection diagnosed on a nasopharyngeal swab sample using the Cepheid GenExpert instrument system -Rapid Real Time Polymerase Chain Reaction (RT-PCR) at the Detroit Medical Center from April 4, 2020-June 5, 2020. Patients without a serial high-sensitivity troponin I (hs-cTnI) on admission and those transferred to our center from an outside hospital were excluded.

MCI during hospitalization was defined as any hs-cTnI>100 ng/L, which corresponds to >99th percentile of the upper reference limit (Manufacture: Beckman Coulter) (7) .

J o u r n a l P r e -p r o o f Only the initial RT-PCR result was included. The Ct value can be used to estimate the number of viral particles in a patient's sample in such a way that every 3.3 decrease in Ct value indicates a log10 (10-fold) increase in target concentration. Using a quantified standard, we found a linear relationship between viral load and Ct value over multiple "1 to 10" dilutions of standard. At 2x10 2 and 2x10 4 viral particles, the Ct values were 43 and 36.7 respectively. Based on our published research (AA: plz provide reference), we designated high, intermediate, and low iVL samples to have a Ct value of ≤25, 26-36, and ≥37 respectively. Subseqnently, we combined the intermediate and the high iVL categories and dichotomized the study population into the low and elevated iVL groups. The lower limit of detection of the assay used is approximately 250 genome copies/mL (95% confidence).

Analysis was performed using SPSS (version 25, IBM) while graphical representations were done on GraphPad Prism (Version 9.0.1). Continuous variables were represented by the median and interquartile range. Chi-square analysis and Fisher's exact test were used to compare categorical variables, while the Mann Whitney U test and Student's t-test were used for continuous variables. A multivariable logistic regression was performed to assess predictors of mortality among patients admitted with SARS-COV-2. Survival analysis of groups of patients stratified by VL level and MCI was performed and a Log-rank test was deployed to identify difference between the 3 groups of interest. Statistical analyses were considered significant if p ≤ 0.05.

The Institutional Review Board at Wayne State University / Detroit Medical Center reviewed the study protocol and ethical approval for the conduction of this study was granted (IRB No. Patients with elevated iVL were older (74 vs 65 years, p <0.001), more likely to reside in a nursing home facility (41.5% vs 29.3%, p=0.045), and had a shorter duration from symptoms onset to PCR results. Patients who developed MCI during hospitalization were older (77 vs 64 years, p =0.02) and had previous history of coronary artery disease (34.1% vs 18.1%, p=0.004) and cerebrovascular disease (47.7% vs 32.4%, p=0.015). During their hospitalization, patients with evidence of MCI had a higher rate of respiratory failure requiring intubation (47.7% vs 27.5%, p=0.001) compared to patients with no MCI. In contrast, there was no significant difference in the percentage of patients who developed respiratory failure among the groups with low and iVL (34.5% vs 33.3%, respectively, p=0.8).

There was no significant difference in the incidence of MCI between low and elevated iVL groups survival rate at 30-day follow up.

Our study showed no association between cardiac injury and elevated viral load. However, it was possible to risk-stratify patients with SARS-CoV-2 infection into three distinct groups based on survival rates, with the worst outcomes in those with simultaneous MCI and elevated viral load.

Cardiac injury is common among patients with SARS-CoV-2 infection(1-3), though its pathogenesis is not yet fully understood. Various, but often overlapping mechanisms of cardiac injury in SARS-CoV-2 infected patients have been proposed and these include oxygen supplydemand imbalance, direct invasion of the myocardium, inflammation, microvascular thrombosis, plaque rupture and stress cardiomyopathy (9) .

The mechanism of SARS-CoV-2 invasion and intracellular replication is facilitated by the binding of the viral envelope S-protein to the ACE2 receptor on the host cell membrane, a transmembrane protein that is expressed in lung, blood vessels, heart, kidneys and intestines. This is followed by viral entry into the cell, triggering a cascade of events leading to viral replication and eventual release from the cell (10) . Cardiac autopsies in patients with SARS-CoV-2 infection showed that the virus can reside in cardiomyocytes even in the absence of clinical and laboratory evidence of cardiac injury (11) . Common histopathologic findings included intracellular edema, thrombi and neutrophilic plugs and interstitial macrophage infiltration (11, 12) . In one study, SARS-CoV-2 were only sporadically present in cardiomyocytes at later stages of the infection (12) suggesting that a maladaptive immune response rather than direct tissue infection is responsible for end-organ damage seen in affected patients. This was echoed by Duerr et al who supported an association between hyperinflammation and myocardial damage in SARS-CoV-2 infection, with higher CD8/regulatory T-cells /monocyte ratios seen in patients who developed respiratory failure or died (13) .

Our study was limited by its average sample. Additionally, since the objective of the study was to examine the association between the VL level and MCI, time to hs-cTnI>100 ng/L was not assessed. This may affect generalizability of the findings and their applicability to different situations. Finally, VL levels were estimated in specimens collected using nasopharyngeal swabs which likely represent the most employed diagnostic modality for SARS-CoV-2 infection. While a recent study found a significantly higher rate of MCI in patients with higher viremia or viral load in the blood (76% vs 37%, p=0.0004) (14) , our study didn't find such association using swab J o u r n a l P r e -p r o o f

Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019: Results of a Multicenter Study

Cardiac Injury Patterns and Inpatient Outcomes Among Patients Admitted With COVID-19

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases

Impact of SARS-CoV-2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients with Coronavirus Disease

Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19

Diagnostic performance of cardiac Troponin I for early rule-in and rule-out of acute myocardial infarction: Results of a prospective multicenter trial

Declining Trend in the Initial SARS-CoV-2 Viral Load During the Pandemic: Preliminary Observations from Detroit

Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia: JACC Focus Seminar

Pathogenesis of SARS-CoV-2 induced cardiac injury from the perspective of the virus

Evidence of SARS-CoV-2 Transcriptional Activity in Cardiomyocytes of COVID-19 Patients without Clinical Signs of Cardiac Involvement

Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study

Parameters predicting COVID-19-induced myocardial injury and mortality

Increased Prevalence of Myocardial Injury in Patients with SARS-CoV-2 Viremia

Platelet Count (K/µL)